LENZ Therapeutics, Inc. (LENZ) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Lens Therapeutics (LENZ) Q1 2026: Three-Month Rx Share Hits 66%, Signaling Early Patient Persistence
May 12, 2026
-
LENZ (LENZ) Q4 2025: 45,000 Prescriptions Signal Early Momentum as Presbyopia Category Takes Shape
March 24, 2026
-
Lens Therapeutics (LENZ) Q3 2025: 5,000 Paid Scripts Signal Category-Creating Launch Momentum
November 05, 2025
-
Lens Therapeutics (LENZ) Q1 2025: SG&A Up 19% as LNZ100 Pre-Launch Build Intensifies
July 04, 2025